Yolanda Aguilera García-rekin lankidetzan egindako argitalpenak (8)

2020

  1. Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus (Frontiers in Immunology, (2019), 10, 10.3389/fimmu.2019.01151)

    Frontiers in Immunology

2019

  1. Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus

    Frontiers in Immunology, Vol. 10, Núm. JUN

  2. Human mesenchymal stem cells prevent neurological complications of radiotherapy

    Frontiers in Cellular Neuroscience, Vol. 13

2018

  1. PDGF Restores the Defective Phenotype of Adipose-Derived Mesenchymal Stromal Cells from Diabetic Patients

    Molecular Therapy, Vol. 26, Núm. 11, pp. 2696-2709

  2. miR-7 Modulates hESC Differentiation into Insulin-Producing Beta-like Cells and Contributes to Cell Maturation

    Molecular Therapy - Nucleic Acids, Vol. 12, pp. 463-477

2016

  1. Derivation of HVR1, HVR2 and HVR3 human embryonic stem cell lines from IVF embryos after preimplantation genetic diagnosis (PGD) for monogenic disorder

    Stem Cell Research, Vol. 16, Núm. 3, pp. 635-639

  2. Impact of transient down-regulation of DREAM in human embryonic stem cell pluripotency. The role of DREAM in the maintenance of hESCs.

    Stem Cell Research, Vol. 16, Núm. 3, pp. 568-578

2013

  1. Zebularine regulates early stages of mESC differentiation: Effect on cardiac commitment

    Cell Death and Disease, Vol. 4, Núm. 4